Novo Nordisk Shares Under Pressure as US Pricing Deal and Acquisition Battle Intensify

Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a significant pricing agreement with US authorities and an escalating bidding war for a key biotechnology firm. The developments have sparked concerns among investors about the company’s ability to balance revenue pressures with strategic expansion needs.

US Pricing Agreement Slashes Medication Costs

In a move that will substantially reduce patient expenses, Novo Nordisk and competitor Eli Lilly have reached a settlement with the US government regarding pricing for GLP-1 medications, including the weight-loss treatment Wegovy. The arrangement, confirmed on Thursday, November 6, will lower monthly costs for Medicare, Medicaid, and self-paying patients to a range of $149 to $350. Previously, these medications carried price tags between $500 and $1,000 monthly.

Company leadership anticipates this pricing shift will negatively impact global revenue growth by a “low single-digit” percentage next year. However, management expects that increased sales volume through Medicare programs will help offset these losses over the medium term. The market response was immediate, with Novo Nordisk shares falling as much as 3% during trading on Friday, November 7, before partially recovering.

Intensifying Competition in Obesity Treatment Market

Simultaneously, Novo Nordisk has become embroiled in a heated acquisition contest with Pfizer for control of biotechnology company Metsera, which specializes in obesity treatments. The Danish firm has submitted an unsolicited higher bid for the company, signaling the strategic importance it places on strengthening its position in the competitive GLP-1 marketplace.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

CEO Lars Fruergaard Jørgensen reinforced this commitment during a Friday press conference, publicly challenging Pfizer to make a definitive decision regarding the acquisition. Securing Metsera is viewed as crucial for Novo Nordisk to maintain its competitive edge against Eli Lilly in the rapidly expanding obesity and metabolic treatment sector.

Market Experts Divided on Long-Term Outlook

Financial analysts remain split on Novo Nordisk’s prospects following these developments. Some researchers have downgraded their ratings on the company’s shares, citing anticipated revenue challenges in 2026. Other market strategists, however, see potential in the pricing strategy to drive substantial volume growth over time.

Political pressure to reduce pharmaceutical pricing is not a new phenomenon for the industry, though Novo Nordisk had already been compelled to revise its annual forecasts downward recently. The central question facing investors is whether the company can successfully navigate the dual challenges of margin compression and strategic expansion through acquisition.